PR PolyResearch

Join Free

AMEX

Pelthos Therapeutics Inc. (PTHS)

♥ 357 Thanks from members

Pelthos Therapeutics Inc. (PTHS) displays robust commercial growth driven by Zelsuvmi adoption, offset by widening net losses, heavy leverage, and near-term earnings misses despite strong analyst backing.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Other NYSE American (AMEX) Tickers

iShares Top 20 U.S. Stocks ETF (TOPT)

Tema U.S. Manufacturing & Reshoring ETF (WELD)

Gabelli Opportunities in Live and Sports ETF (GOLS)

MicroSectors FANG+ 3X Leveraged ETNs (FNGU)

iShares U.S. Pharmaceutical ETF (IHE)

iShares Core 80/20 Aggressive Allocation ETF (AOA)